Building a Stronger Life Sciences Network in Georgia

Building a Stronger Life Sciences Network in Georgia



February 26, 2025-We are excited to invite you to take an active role in shaping the future of Georgia's life sciences community. Whether you're an experienced professional or passionate about making an impact, there are opportunities for you to contribute, grow, and connect with fellow leaders in the field.

 

Georgia Life Sciences currently has several new groups that will work together to support and advance Georgia's life sciences industry: 

 

1. Mentorship Network:
This initiative connects emerging professionals with experienced mentors in the life sciences space. By sharing your expertise and guidance, you'll help foster the next generation of innovators, scientists, and entrepreneurs. Become a mentor.

 

2. Summit Planning Committee:
The Life Sciences Summit is one of Georgia's premier events, and we need your help in organizing a memorable and impactful experience. As a committee member, you'll have the opportunity to influence the agenda, secure speakers, and collaborate with industry leaders to showcase Georgia's life sciences sector. Apply today.

 

3. Entrepreneurship Committee:
Georgia is home to a vibrant community of biotech, medtech, and pharma innovators. The Entrepreneurship Subcommittee is dedicated to helping startups and growing companies navigate challenges, access resources, and scale effectively. We need forward-thinking individuals to support and mentor this dynamic ecosystem. Learn about our committees.

 

4. Emerging Leaders Network:

Georgia Life Sciences' Emerging Leaders Network builds strong, supportive networks for PhDs, postdoctoral fellows, and early career professionals, and leverages the state’s life sciences connectivity to foster growth, collaboration, and career advancement opportunities. Seasoned individuals will provide invaluable advice, guidance, and mentorship, leveraging their experiences and insights to help new leaders avoid common pitfalls and accelerate their growth. Join the collective.

 

5. HR Network:

Our HR network serves as a place where HR professionals may come together to focus on organizational development and talent management specific to Georgia’s life sciences industry. Join the network.

 

6. Manufacturing Council:

The Georgia Life Sciences’ Manufacturers Council was established to provide late stage clinical and commercial phase members with a vehicle to advocate for industry interests, including but not limited to quality, regulatory, infrastructure, safety, and workforce training issues. Join the Council. 

 

Why Get Involved?

  • Make an Impact: Play a crucial role in shaping the future of life sciences in Georgia.
  • Expand Your Network: Connect with like-minded professionals, innovators, and leaders.
  • Grow Professionally: Contribute to meaningful projects that will enhance your skill set and build your resume.

 

We would love for you to be part of one of these exciting initiatives and encourage you to share with your contacts.

 

If you are interested in joining any of these groups or would like more information, please reach out to Stacey Bowlin, sbowlin@galifesciences.org, or simply reply to this email.

 

Thank you for considering these opportunities. We look forward to your participation!

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

By Maria Thacker Goethe • October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape

Georgia Life Sciences Launches New Podcast Series, Vitals, in Partnership with Cloudcast Media

October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS